Pharma Pulse: GLP-1 Momentum Builds While Lilly Expands Genetic Medicine Manufacturing

Key Takeaways

• Lilly's Indiana plant expands U.S. genetic therapy capacity.
• GLP‑1 drugs represent 8% of U.S. prescriptions in March 2026.
• Bayer adds ophthalmology portfolio by buying Perfuse Therapeutics.
• FDA authorizes fruit‑flavored ENDS, marking regulatory shift.
• Madrigal and Arrowhead license ARO‑PNPLA3 for MASH treatment.

Pulse Analysis

Eli Lilly’s new 150,000‑square‑foot facility in Lebanon, Indiana marks the company’s first dedicated site for genetic medicines, a segment projected to exceed $30 billion globally by 2030. By co‑locating development and manufacturing, Lilly shortens timelines for gene‑editing and RNA‑based therapies, positioning itself against rivals such as Moderna and CRISPR Therapeutics. The plant also supports the U.S. push for domestic biomanufacturing, reducing reliance on overseas contract manufacturers and strengthening supply‑chain resilience for high‑value biologics. The plant is expected to create 400 direct jobs and attract ancillary suppliers, reinforcing Indiana’s biotech corridor.

GLP‑1 agonists captured eight prescriptions per 100 filled in March 2026, underscoring their rapid diffusion beyond diabetes into obesity and cardiovascular care. The surge reflects aggressive marketing, expanding insurance coverage, and compelling clinical data that show weight loss of up to 15 percent. As payers adjust formularies, manufacturers such as Novo Nordisk and Eli Lilly anticipate a multi‑billion‑dollar revenue runway, while competitors scramble to launch next‑generation peptides to protect market share. Future formulary negotiations will likely tie reimbursement to outcomes, prompting manufacturers to invest in real‑world evidence programs.

Bayer’s $1.2 billion acquisition of Perfuse Therapeutics adds an injectable gene‑therapy platform focused on retinal diseases, bolstering its ophthalmology pipeline ahead of a projected $12 billion market by 2028. Simultaneously, Madrigal’s licensing deal with Arrowhead for ARO‑PNPLA3 signals intensified interest in non‑alcoholic steatohepatitis (MASH) treatments, a therapeutic area with few approved options. The FDA’s approval of fruit‑flavored electronic nicotine delivery systems further illustrates a shifting regulatory stance, potentially opening new revenue streams for tobacco‑aligned firms while raising public‑health debates. Analysts project Bayer’s eye‑care revenue could rise 15 percent annually, while the ENDS ruling may spur a wave of flavored product applications.